Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors

Blood. 2003 Mar 1;101(5):1734-43. doi: 10.1182/blood-2002-03-0823. Epub 2002 Oct 24.

Abstract

High-capacity adenoviral (HC-Ad) vectors expressing B-domain-deleted human or canine factor VIII from different liver-specific promoters were evaluated for gene therapy of hemophilia A. Intravenous administration of these vectors into hemophilic FVIII-deficient immunodeficient SCID mice (FVIIIKO-SCID) at a dose of 5 x 10(9) infectious units (IU) resulted in efficient hepatic gene delivery and long-term expression of supraphysiologic FVIII levels (exceeding 15 000 mU/mL), correcting the bleeding diathesis. Injection of only 5 x 10(7) IU still resulted in therapeutic FVIII levels. In immunocompetent hemophilic FVIII-deficient mice (FVIIIKO), FVIII expression levels peaked at 75 000 mU/mL but declined thereafter because of neutralizing anti-FVIII antibodies and a cellular immune response. Vector administration did not result in thrombocytopenia, anemia, or elevation of the proinflammatory cytokine interleukin-6 (IL-6) and caused no or only transient elevations in serum transaminases. Following transient in vivo depletion of macrophages before gene transfer, significantly higher and stable FVIII expression levels were observed. Injection of only 5 x 10(6) HC-Ad vectors after macrophage depletion resulted in long-term therapeutic FVIII levels in the FVIIIKO and FVIIIKO-SCID mice. Intravenous injection of an HC-Ad vector into a hemophilia A dog at a dose of 4.3 x 10(9) IU/kg led to transient therapeutic canine FVIII levels that partially corrected whole-blood clotting time. Inhibitory antibodies to canine FVIII could not be detected, and there were no signs of hepatotoxicity or of hematologic abnormalities. These results contribute to a better understanding of the safety and efficacy of HC-Ad vectors and suggest that the therapeutic window of HC-Ad vectors could be improved by minimizing the interaction between HC-Ad vectors and the innate immune system.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviruses, Human / genetics*
  • Animals
  • Antibodies, Heterophile / biosynthesis
  • Antibodies, Heterophile / immunology
  • Apolipoprotein C-II
  • Apolipoproteins C / genetics
  • Apolipoproteins E / genetics
  • Clodronic Acid / pharmacology
  • DNA, Recombinant / analysis
  • DNA, Recombinant / genetics
  • Dog Diseases / genetics
  • Dog Diseases / therapy
  • Dogs
  • Factor VIII / analysis*
  • Factor VIII / genetics
  • Factor VIII / immunology
  • Genes, Synthetic
  • Genetic Therapy*
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Genetic Vectors / therapeutic use*
  • Hemophilia A / blood
  • Hemophilia A / genetics
  • Hemophilia A / therapy*
  • Hemophilia A / veterinary
  • Hemorrhage / prevention & control
  • Injections, Intravenous
  • Liver / metabolism
  • Liver Function Tests
  • Macrophages / drug effects
  • Macrophages / physiology
  • Mice
  • Mice, Inbred NOD
  • Mice, Knockout
  • Mice, SCID
  • Models, Animal
  • Promoter Regions, Genetic
  • RNA, Messenger / biosynthesis
  • Species Specificity

Substances

  • Antibodies, Heterophile
  • Apolipoprotein C-II
  • Apolipoproteins C
  • Apolipoproteins E
  • DNA, Recombinant
  • RNA, Messenger
  • Clodronic Acid
  • Factor VIII